First year of data | 2010–2014* | 2015* | 2016* | 2017* | ||||||||
Total cases | Prevalence per 10 000 births (95% CI) | Total cases (CZS cases) | Prevalence per 10 000 births (95% CI) | PRR versus 2010–2014 (95% CI) | Total cases (CZS cases) | Prevalence per 10 000 births (95% CI) | PRR versus 2010–2014 (95% CI) | Total cases (CZS cases) | Prevalence per 10 000 births (95% CI) | PRR versus 2010–2014 (95% CI) | ||
Argentina | 2010 | 240 | 2.37 (2.09 to 2.70) | 60 | 1.79 (1.37 to 2.31) | 0.8 (0.6 to 1.0) | 77 (5) | 2.52 (1.99 to 3.15) | 1.1 (0.8 to 1.4) | 78† | 2.85 (2.25 to 3.55) | 1.2 (0.9 to 1.6) |
Chile Maule | 2010 | 6 | 0.62 (0.13 to 2.86) | 2 | 1.42 (0.17 to 5.14) | 1.6 (0.3 to 8.1) | 5 | 3.78 (1.23 to 8.82) | 4.4 (1.3 to 14.3) | 4 | 3.02 (0.82 to 7.74) | 3.5 (1.0 to 12.4) |
Chile National‡ | 2016 | No data | No data | 52 | 4.03 (3.01 to 5.28) | – | 69 | 5.06 (3.93 to 6.40) | – | |||
Colombia Bogota§ | 2014 | 12 | 1.16 (0.60 to 2.02) | 31 | 3.02 (2.05 to 4.28) | 2.6 (1.3 to 5.1) | 105 | 10.64 (8.71 to 12.88) | 9.2 (5.1 to 16.7) | 68 | 7.39 (5.74 to 9.36) | 6.4 (3.5 to 11.8) |
Colombia Cali | 2010 | 5 | 0.35 (0.15 to 0.85) | 1 | 0.37 (0.01 to 2.04) | 1 (0.1 to 8.9) | 67 (1) | 25.59 (19.83 to 32.50) | 72.7 (29.3 to 180.5) | 23 | 8.66 (5.49 to 12.99) | 24.6 (9.4 to 64.7) |
Costa Rica | 2010 | 158 | 4.09 (2.90 to 5.76) | 27 | 3.76 (2.48 to 5.47) | 0.9 (0.6 to 1.3) | 60 (3) | 8.57 (6.54 to 11.03) | 2 (1.5 to 2.6) | 146 (17) | 21.22 (17.92 to 24.95) | 4.8 (3.9 to 6.1) |
Mexico, Nuevo Leon | 2015 | 0 | 1 | 0.11 (0.00 to 0.60) | – | 5 | 0.54 (0.17 to 1.25) | – | 6 (3) | 0.67 (0.25 to 1.47) | – | |
Nicaragua | 2011 | 9 | 2.16 (1.12 to 4.15) | 2 | 1.9 (0.23 to 6.86) | 0.9 (0.2 to 4.1) | 8 | 8.06 (3.48 to 15.88) | 3.7 (1.4 to 9.7) | 22 | 22.37 (14.02 to 33.87) | 10.4 (4.8 to 22.5) |
All centres, excl Brazil | 430 | 2.27 (2.02 to 2.56) | 124 | 2.32 (1.93 to 2.78) | 379 | 5.36 (4.78 to 6.00) | 416 | 5.89 (5.27 to 6.58) | ||||
Brazil | 2010 | 852 | 0.58 (0.54 to 0.63) | 1756 (NA) | 5.82 (5.55 to 6.10) | 9.9 (9.2 to 10.8) | 2273 (NA) | 7.95 (7.63 to 8.29) | 13.6 (12.6 to 14.7) | 559 (NA) | 1.91 (1.76 to 2.08) | 3.3 (2.9 to 3.6) |
NA, data not provided.
*Time periods selected as 2010–2014 is pre-congenital Zika syndrome for all registries, in 2015 congenital Zika syndrome occurred in Brazil and in 2016 congenital Zika syndrome occurred in remaining registry areas apart from Chile where congenital Zika syndrome did not occur.
†Number of cases for Argentina 2017 was obtained from National report (http://www.anlis.gov.ar/cenagem/?page_id=33).
‡Chile National excludes Chile (Maule).
§For Colombia-Bogota, data were only available for 2014–2017. Estimates for 2015–2017 are thus relative only to 2014.
PRR, prevalence rate ratio.